We expect roll out of insulin glargine in Europe to start in second half of 2018, says Biocon


Biocon on Friday said it expects its partner Mylan to launch insulin glargine across various markets in Europe in the second half of 2018. The company didn’t specify the Australian launch but said it will happen later this year.Biocon and its partner Mylan on Thursday said they have received approval for insulin glargine in Europe and Australia. After Japan, Europe and Australia were two highly regulated markets that the company has approval to sell the long acting insulin – the biosimilar version of French drug maker Sanofi’s Lantus.Below is an edited excerpt from email interview with Siddharth Mittal, President – Finance of Biocon.